Clinical and sequencing data

Sheet 1 contains clinical data for the 5,649 patients included in the manuscript. Patients are numbered consecutively - sample1 through sample5649. MeanCoverage is coverage from blood sequencing. Presence/absence of mutations in top 5 recurrently mutated genes are depicted in addition to presence/absence of clonal hematopoiesis (CH) or clonal hematopoiesis in a presumptive driver (CH-PD). Additional clinically relevant variables include age at time of blood draw, gender, race, vital status, days to last follow up, prior exposure to chemotherapy and/or radiation therapy, laboratory parameters at time of blood sampling (including white blood cell cunt, hemoglobin, mean corpuscular volume, absolute neutrophil, lymphocyte and monocyte counts, platelet count, red-cell distribution width, record of prior blood transfusion (all), platelet transfusion (only), red blood cell transfusion (only), and prior receipt of growth factor.

Sheet 2 contains mutation calls for all patients who were determined to have either CH. Of note is that for sample1-sample5649, only those patients from sheet 1 with CH were included on sheet 2. For sample5650 to sample6509, these are all patients with CH variants from the larger subset of sequenced patients (8,810 patients in total). This sheet includes mutated gene, and nomenclature for both cDNA and amino acid change, in addition to the variant allele frequency of the mutation in both the blood and the tumor tissue. Lastly it describes whether any given CH mutation is defined as a CH-PD mutation.

第一页包含了论文中涉及到的5,649名患者的临床数据。患者按顺序编号，从样本1至样本5649。平均覆盖度代表血液测序的覆盖情况。此外，图表中展示了前五位高频突变基因突变的有无，以及克隆性造血（CH）或克隆性造血在假设驱动因素中的存在与否（CH-PD）。其他与临床相关的变量包括抽血时的年龄、性别、种族、生命体征、最后随访天数、先前接触化疗和/或放疗、血液采集时的实验室参数（包括白细胞计数、血红蛋白、平均红细胞体积、绝对中性粒细胞、淋巴细胞和单核细胞计数、血小板计数、红细胞分布宽度、先前输血记录（全部）、仅血小板输血、仅红细胞输血，以及先前接受生长因子的记录。第二页包含了被确定具有克隆性造血（CH）的所有患者的突变调用。值得注意的是，对于样本1至样本5649，仅包括第一页中具有CH的患者。对于样本5650至样本6509，这些患者均来自更大序列患者子集的克隆性造血变体（总共有8,810名患者）。此页包括突变基因，以及cDNA和氨基酸变化的命名，此外还描述了血液和肿瘤组织中突变变异等位基因频率。最后，还说明了任何特定的CH突变是否定义为克隆性造血在假设驱动因素中的突变。